1

2	Investigating psychobiological causes and mechanisms in functional
3	seizures and functional motor symptoms: Study protocol
4	
5	Susannah Pick ¹ *, Anthony S. David ² , Mark J. Edwards ¹ , Laura H. Goldstein ¹ , John Hodsoll ¹ ,
6	L. S. Merritt Millman ¹ , Timothy R. Nicholson ¹ , A.A.T.S. Reinders ¹ , Biba Stanton ^{1,3} , Joel S.
7	Winston ^{1,3} , Mitul A. Mehta ¹ , Trudie Chalder ¹ , Matthew Hotopf ^{1,4}
8 9 10 11 12 13	¹ Institute of Psychiatry, Psychology & Neuroscience, King's College London ² Instutite of Mental Health, University College London ³ King's College Hospital NHS Foundation Trust ⁴ South London & Maudsley NHS Foundation Trust
14	Corresponding author: Dr Susannah Pick*
15	Address: Department of Psychological Medicine, Institute of Psychiatry, Psychology &
16	Neuroscience, King's College London, 16 De Crespigny Park, London, SE5 8AF
17	Email: susannah.pick@kcl.ac.uk
18	
19	Word count: 5200
20	
21	
22 23	
24	

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/2024.05.24.24307863; this version posted May 25, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Short title – Investigating datases and all the median of the PND: Store in the preprint of the preprint in perpetuity.

25 Abstract

26

27 Introduction: Advances have been made in understanding the aetiology of functional

- neurological disorder (FND); however, its pathophysiological mechanisms have not been
- 29 definitively demonstrated. Evidence suggests interacting roles for altered emotional
- 30 processing and interoception, elevated autonomic arousal, and dissociation, but there is
- 31 limited evidence demonstrating their causal influence on specific FND symptoms. Our
- 32 superordinate aim is to elucidate potentially shared and distinct aetiological factors and
- mechanisms in two common FND subtypes, functional seizures (FS) and functional motor
- 34 symptoms (FMS).
- **Methods:** This study has a multimodal, mixed between- and within-groups design. The target
- sample is 50 individuals with FS, 50 with FMS, 50 clinical controls (anxiety/depression), and
 50 healthy controls. Potential aetiological factors (e.g., adverse life events, physical/mental
- 37 50 health y controls. Potential aetological factors (e.g., adverse file events, physical/mental
 38 health symptoms, dissociative tendencies, interoceptive insight/sensibility) will be assessed
- with a detailed medical history interview and self-report questionnaires. A laboratory session
- 40 will include a neurocognitive battery, psychophysiological testing, cardiac interoception and
- 40 with include a neurocognitive battery, psychophysiological testing, earling incroception and 41 time estimation tasks and an isometric handgrip task. A subsample will undergo magnetic
- 42 resonance imaging, including structural, resting-state and task-based scans combined with
- 43 psychophysiological recording. Remote monitoring with ecological momentary assessment
- 44 and wearables will measure variability in FND symptoms and in patients' daily lives and
- their potential predictors/correlates for ≥ 2 weeks. Longitudinal follow-ups at 3, 6, and 12-
- 46 months will monitor longer-term outcomes in the clinical groups.
- **Discussion:** This study employs multimodal research methods to rigorously examine several
- putative mechanisms in FND, at subjective/experiential, behavioural, and physiological
 levels. The study will test causal hypotheses about the role of altered emotional processing.
- autonomic arousal, dissociation and interoception in the initiation or exacerbation of FND
- 51 symptoms, directly comparing these processes in FS and FMS to healthy and clinical
- 52 controls. This is the first study of its kind, with potential to reveal important targets for
- 53 prevention and treatment of FND in future.
- 54
- 55
- 56
- 57 Key Words: non*epileptic seizures; conversion disorder; dissociative seizures; functional
 58 movement disorder; digital; MRI.
- 59

medRxiv preprint doi: https://doi.org/10.1101/2024.05.24.24307863; this version posted May 25, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Short title – Investigating datases and all the medical problem of the problem of the preprint in perpetuity.

60 Introduction

Functional neurological disorder (FND) is a complex neuropsychiatric disorder defined by 61 the presence of neurological symptoms (motor, sensory, seizure) that are not caused by or 62 compatible with identifiable neuropathology (APA, 2013; WHO, 2019). FND is commonly 63 associated with impaired quality of life, diminished functioning, psychological distress and 64 significant healthcare costs (Carson & Lehn, 2016). Individuals with FND experience 65 considerable stigma and barriers to accessing appropriate treatment, which is exacerbated by 66 uncertainty regarding causation and mechanisms. 67 It is now accepted that there is a wide range of psychological, social and biological 68 aetiological factors associated with FND, including stressful life events, mental health 69 symptoms/disorders, relationship problems and significant physical injuries and illnesses 70 (Brown & Reuber, 2016; Morsy et al., 2021; Reuber, 2009). However, precisely how these 71 factors contribute to FND is still not fully understood and there is a need for more rigorous 72 research into the mechanisms underlying FND symptoms. 73 Recent perspectives have highlighted the potential role of altered emotional 74 information processing and elevated autonomic arousal in FND (Brown & Reuber, 2016; 75 Drane et al., 2020; Pick et al., 2019). Previous experimental evidence has shown that people 76 77 with FND exhibit differences in autonomic and/or subjective responses to affective stimuli (e.g., Pick, Mellers & Goldstein, 2018a; Pick et al., 2023; Roberts et al., 2012), reduced 78 recognition and attentional biases to emotional facial expressions (Bakvis et al., 2009; Pick, 79 80 Mellers & Goldstein, 2016; 2018b), altered bodily awareness (interoception) (Koreki et al., 2020; Pick et al., 2020; Williams et al. 2021), and divergent patterns of neural activation 81 during exposure to affective stimuli (e.g., Aybek et al., 2015; Espay et al., 2018). There is 82 83 also accumulating evidence to support the view that dissociation may be an important

underlying pathophysiological process (e.g., Campbell et al., 2022; Koreki et al., 2020; Pick,
Mellers & Goldstein, 2017; Pick et al., 2020).

86	Despite advances in the understanding of FND, there remain some important
87	unanswered questions. Firstly, few studies have examined explicitly the potential temporal
88	relationships between key pathophysiological processes (e.g., autonomic arousal, limbic
89	hyperactivation) and the occurrence of FND symptoms (Pick et al., 2019). Evidence for
90	causal relationships between putative mechanistic processes and FND symptoms is therefore
91	limited, with many previous studies demonstrating only correlational relationships. There is a
92	paucity of studies directly comparing potential causal factors and pathophysiological
93	mechanisms in different FND subtypes, and the possible links between background
94	aetiological factors and mechanistic processes in these subgroups require further
95	examination. Furthermore, there is little evidence linking specific aetiological factors and
96	mechanistic processes to longer-term outcomes in FND.
97	
98	Aims & objectives
98 99	<i>Aims & objectives</i> The overall aim of this project is to elucidate the shared and distinct psychobiological causes
99	The overall aim of this project is to elucidate the shared and distinct psychobiological causes
99 100 101	The overall aim of this project is to elucidate the shared and distinct psychobiological causes and mechanisms of functional seizures (FS) and functional motor symptoms (FMS), using a novel combination of multi-modal research methods.
99 100 101 102	The overall aim of this project is to elucidate the shared and distinct psychobiological causes and mechanisms of functional seizures (FS) and functional motor symptoms (FMS), using a novel combination of multi-modal research methods. The primary objective is to examine the hypothesised influence of autonomic arousal
99 100 101	The overall aim of this project is to elucidate the shared and distinct psychobiological causes and mechanisms of functional seizures (FS) and functional motor symptoms (FMS), using a novel combination of multi-modal research methods.

105	•	Assess a range of biological, psychological and social aetiological factors in people
106		with FS and FMS, including adverse life events, psychological distress and
107		dissociative tendencies.
108	•	Examine relationships between background factors (e.g., adverse experiences),
109		psychobiological mechanisms (e.g., autonomic arousal, limbic hyperactivity, bodily
110		awareness) and clinical outcomes (i.e., symptom severity, functioning, quality of life).
111	٠	Identify the similarities and differences in background factors and pathophysiological
112		processes in the FND groups (FS, FMS) relative to individuals with elevated
113		psychological symptoms (anxiety, depression), who do not experience neurological
114		symptoms.
115	•	Examine factors that might trigger the occurrence or worsening of FS and FMS
116		symptoms in patients' daily lives in real-world contexts, including the possible
117		influence of autonomic arousal, sleep disturbance, physical exertion, daily events and
118		mood variations.
119	To ach	nieve these objectives, the following methods are being employed:
120	•	An in-depth interview and self-report questionnaires to capture data on a range of
121		possible predisposing, precipitating and perpetuating factors.
122	•	Standardised neurocognitive tests to examine core cognitive domains implicated in
123		the pathophysiology of FND, including attention (Edwards et al., 2012), executive
124		functions (Brown & Reuber, 2016), and social cognition (Pick et al., 2019).
125	•	Experimental and psychophysiological measures to probe behavioural, cognitive and
126		physiological responses to bodily sensations and affectively significant stimuli.
127	•	Neuroimaging to assess structural and functional brain differences in people with FS
128		and FMS, compared to both healthy and clinical controls.

129	•	Remote monitoring with smartphone applications and a wearable device to collect
130		data on the possible antecedents of FS and FMS in 'real-time' and 'real-world'
131		contexts.
132	•	Remote follow-up sessions at 3, 6, and 12-months to examine longer-term clinical
133		outcomes.
134		
135	The pr	imary hypotheses being tested are:
136	1.	Individuals with FS and FMS will exhibit elevated autonomic activation (heart rate,
137		electrodermal activity) in response to affectively significant stimuli and events,
138		compared to healthy and clinical controls.
139	2.	Elevated autonomic arousal and associated hyperactivation in limbic brain regions
140		will temporally precede the occurrence or exacerbation of FS and FMS.
141		
142	The se	econdary hypotheses include the following:
143	1.	People with FS and FMS will display alterations in bodily awareness (interoception)
144		and associated neural activity, compared to controls.
145	2.	Participants with FS and FMS will exhibit differences in executive functioning (e.g.,
146		attentional allocation, response inhibition) and social cognition compared to controls,
147		despite intact general cognitive functioning.
148	3.	FS and FMS symptom severity will be exacerbated in daily life by emotionally salient
149		events, dissociation, and negative affect.
150	4.	Worse clinical outcomes (symptom severity, quality of life, functioning,
151		psychological distress) will be predicted by adverse life event burden, elevated
152		autonomic arousal, limbic hyperactivation, and greater psychological dissociation.

153 Materials and methods

154	This study underwent peer-review by four independent reviewers during funding acquisition
155	(Medical Research Council UK) and has been reviewed/approved by the Health Research
156	Authority and an NHS Research Ethics Committee ('Ethical considerations'). This is a single
157	centre study; all research activities are taking place at, or being coordinated from, the
158	Institute of Psychiatry, Psychology and Neuroscience, King's College London.
159	
160	Study Design
161	This project has a mixed between- and within-groups design, including observational,
162	experimental, cross-sectional and longitudinal measures. The FS and FMS samples are being
163	compared to healthy and clinical control groups.
164	
165	Primary endpoints
166	• FS and FMS occurrence and severity, measured with repeated momentary
167	assessments during the laboratory, neuroimaging and remote monitoring procedures.
168	• Autonomic arousal, measured with heartrate and/or electrodermal activity levels
169	during the laboratory, neuroimaging and remote monitoring procedures.
170	• Limbic and paralimbic system hyperactivation, measured with region-of-interest
171	neuroimaging analyses.
172	Secondary endpoints
173	• FS and FMS severity, occurrence, and impact, measured with self-report
174	questionnaires at baseline and 3, 6 and 12-month follow-up.

medRxiv preprint doi: https://doi.org/10.1101/2024.05.24.24307863; this version posted May 25, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Short title – Investigating datases are all all the median of the median of

175	•	Psychological dissociation, measured with momentary assessments during the
176		laboratory, neuroimaging session and remote monitoring phased, and with validated
177		scales at baseline and follow-up.
178	•	Interoceptive accuracy and awareness, and associated functional brain activity (i.e.,
179		insula), measured with experimental tasks and self-report measures at baseline, during
180		the laboratory session and at follow-up, and with region-of-interest analyses in the
181		neuroimaging study.
182	•	Cognitive functioning, measured with standardised neurocognitive tests and
183		experimental tasks during the laboratory session.
184	•	Work, social and physical functioning, measured with validated scales at baseline and
185		at follow-up.
186	•	Health-related quality of life, also measured with a validated questionnaire at baseline
187		and follow-up.
188		
189	Pilot s	tudy
190	The de	esign of this project has been informed by a pilot study which was conducted between
191	July-C	ctober 2022, including 17 participants with FMS and/or FS and 17 healthy controls.

192 The pilot study included all procedures proposed here, except the neuroimaging session. The

aim was to test the acceptability and feasibility of the procedures, and to ensure that the tasks

194 planned for the neuroimaging session were well-tolerated and valid. The 34 participants who

- entered the study completed all elements of the research. Feedback was elicited from
- 196 participants, which has now been incorporated into this protocol. The findings of the pilot
- 197 study have been reported elsewhere (Millman et al., 2023, 2024; Pick et al., 2023a,b).
- 198

199 *Patient/public involvement*

200	An FND Patient and Carer Advisory Panel (FND-PCAP) was convened in 2022 to consult
201	with the team throughout the project on the design, implementation and dissemination of the
202	project. The FND-PCAP includes patients with FND, carers, and representatives of patient
203	support organisations (FND Hope UK, FND Action).
204	
205	Participants
206	Fifty participants diagnosed with FS and 50 with FMS will be recruited in total, in addition to
207	50 healthy control participants and 50 matched clinical control participants. The groups will
208	be frequency-matched for age, sex/gender, and handedness. The eligibility criteria are
209	detailed below.
210	
211	Inclusion criteria
212	All participants:
213	• 18-65 years old
214	• Normal or corrected eyesight
215	• Fluency in English language
216	Participants with FS:
217	• A primary diagnosis of functional seizures made by a Consultant
218	Neurologist/Epileptologist, in the absence of functional motor symptoms
219	• Currently meets DSM-5 criteria for FND
220	• Minimum seizure frequency of 2 per month, with premonitory symptoms
221	Participants with FMS:

medRxiv preprint doi: https://doi.org/10.1101/2024.05.24.24307863; this version posted May 25, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Short title – Investigating datased and aimsted medRata for FND: Standy protocole.

222	• A primary diagnosis of functional motor symptoms made by a Consultant
223	Neurologist, in the absence of functional seizures
224	• Currently meets DSM-5 criteria for FND
225	Clinical control participants:
226	• Presence of anxiety disorder or major depression, confirmed with DSM-5 criteria
227	during the screening interview (Quick SCID)
228	Exclusion criteria
229	All participants:
230	• Diagnosis of major comorbid cardiovascular (e.g., heart disease), active severe
231	psychiatric disturbance (e.g., psychosis, alcohol, or substance dependence) or
232	neurological disorder (e.g., epilepsy, multiple sclerosis) that would either confound
233	the findings or impair the participant's ability to participate
234	• Physical symptoms / disability impairing ability to perform tasks (e.g.,
235	severe/constant tremor, bilateral upper limb paralysis, daily seizures)
236	• Current participation in another interventional study (e.g., treatment trial,
237	experimental study)
238	Neuroimaging study:
239	• Ineligibility to undergo MRI imaging, for example the presence of a cardiac
240	pacemaker or other electronic device or ferromagnetic metal foreign bodies.
241	• Participant weight in excess of 126kg or physical dimensions such that the
242	participant may not fit in the MRI scanner.
243	• A history of claustrophobia or participant reports symptoms triggered in confined
244	spaces or participant feels unable to lie in an MRI scanner for a period of up to 90
245	minutes.

246	• Any other reason that in the opinion of the investigator may impact the safety of
247	participants or the integrity of the data.
248	Healthy control participants:
249	Diagnosis of FND
250	• Active major physical or mental health disorder
251	Clinical control participants:
252	Diagnosis of FND
253	• Active suicidality or non-suicidal self-injury
254	
255	Study procedures
256	Figure 1 details the study procedures including the timepoint at which each measure is
257	administered.
258	(insert Figure 1 near here)
259	Participant recruitment
260	Recruitment of participants commenced in November 2023 and will end in December 2025
261	or when the target sample size is achieved, if earlier.
262	Participants with FND are being referred from neurology and/or neuropsychiatry
263	services at the South London and Maudsley, King's College Hospital, University College
264	Hospitals and St George's University Hospitals NHS Foundation Trusts. Participants with
265	FND are also being recruited online, with advertisements circulated by charitable patient
266	support websites (e.g., FND Hope UK, FND Action). Healthy and clinical control
267	participants are being recruited from the community via advertisements in public places and
268	social media platforms. Clinical control participants will also be recruited from existing KCL

medRxiv preprint doi: https://doi.org/10.1101/2024.05.24.24307863; this version posted May 25, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Short title – Investigating datases deratation of PND: Store of the second second

research cohorts (e.g., the Genetic Links to Anxiety and Depression study

270 [https://gladstudy.org.uk/]).

Potential participants who express interest in the study and appear to be eligible at initial
screening are provided with a Participant Information Sheet (PIS) and Informed Consent Form
(ICF) by their clinician or the research team.

274 275 (insert Figure 1 near here)

276 Informed Consent Procedures

277 There are three written informed consent procedures during this study, as follows:

Main consent form: Participants who appear to be eligible at initial contact are asked to
 complete a consent form electronically for completion of the screening interview,
 background questionnaires, and laboratory session. Consent for this stage is obtained
 at least 48 hours after participants received the PIS/ICF, unless a participant decides to
 participate sooner, in which case they are able to contact the research team directly.

- 283
 2. Neuroimaging: Another ICF is completed for the MRI session, either electronically or
 in person. If seemingly eligible at initial screening, participants are given a separate
 neuroimaging PIS and ICF for consideration for at least 48 hours.
- 3. Remote monitoring: Participants complete another ICF, electronically or in person, for
 participation in the remote monitoring phase, prior to installing the smartphone
 applications on their mobile devices.

289 Consent is obtained at all timepoints by a member of the immediate research team, only after 290 participants' questions have been answered and a full, detailed explanation of the research 291 activities has been provided.

292

293 Screening Procedures

medRxiv preprint doi: https://doi.org/10.1101/2024.05.24.24307863; this version posted May 25, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Short title – Investigating datases and alastes and al

All participants are screened initially for eligibility by either a member of the research team or 294 a local clinician. Potential participants are assessed for eligibility briefly on the basis of current 295 physical or mental health diagnoses, FND symptoms (if applicable), and medications. Those 296 candidates appearing to meet the eligibility criteria are asked to provide informed consent prior 297 298 to participating in a detailed screening interview with a senior member of the research team by telephone or online. During the interview, participants complete a detailed background 299 sociodemographic and medical history questionnaire, followed by a brief structured clinical 300 interview (Quick SCID; First & Williams, 2021). Eligibility for all elements of the study, 301 including neuroimaging, are evaluated at this stage. Following the interview, participants are 302 303 informed of the outcome. Should the candidate not be eligible to progress into the main study, they are given a detailed explanation and reimbursed for their time with a £10 shopping 304 voucher. 305

306

307 Schedule of Assessments

308 *Online self-report questionnaires*

309 Eligible participants are emailed a weblink to a set of self-report questionnaires (Qualtrics),310 which assess the following aetiological factors:

- Life events (Traumatic Experiences Checklist; Nijenhuis, Van der Hart, & Kruger,
 2002)
- Trauma-related distress (Posttraumatic Stress Diagnostic Scale Self-Report Version
 for DSM-5; Foa et al., 2016)
- Work and social functioning (Work and Social Adjustment Scale; Mundt, Marks,
 Shear, & Greist, 2002)

medRxiv preprint doi: https://doi.org/10.1101/2024.05.24.24307863; this version posted May 25, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Short title – Investigating data review article and the second and the sec

317	٠	Health-related quality of life (Short Form Health Survey – 36 item; Hays, Sherbourne,
318		& Mazel, 1993)

- Psychological distress (Patient Health Questionnaire-9; Kroenke, Spitzer, & Williams,
 2001 / Generalized Anxiety Disorder-7; Spitzer, Kroenke, Williams, & Lowe, 2006)
- Physical symptom burden (Patient Health Questionnaire-15; Kroenke, Spitzer, &
 Williams, 2002)
- Interoceptive abilities (Interoceptive Accuracy Scale, Murphy et al., 2020;
 Interoceptive Attention Scale, Gabriele et al., 2022; Multidimensional Assessment of
 Interoceptive Awareness-2, Mehling et al., 2018)
- Dissociative tendencies (Somatoform Dissociation Questionnaire-20; Nijenhuis,
 Spinhoven, Van Dyck, Van der Hart, & Vanderlinden, 1996; Multiscale Dissociation
 Inventory; Briere, 2005)
- Alexithymia (Toronto Alexithymia Scale-20; Bagby, Taylor, & Parker, 1994)
- Autistic traits (Autism Spectrum Quotient; Baron-Cohen, Wheelwright, Skinner,
 Martin, & Clubley, 2001)
- FND symptoms (bespoke questionnaire assessing the presence and severity of FND symptoms)
- Illness-related cognitions (Brief Illness Perceptions Questionnaire; Broadbent, Petrie,
 Main, & Weinman, 2006 / Cognitive Behavioural Responses Questionnaire; Ryan,
 Vitoratou, Goldsmith, & Chalder, 2018)
- Subjective cognitive symptoms (Cognitive Failure Questionnaire; Broadbent, Cooper,
 FitzGerald, & Parkes, 1982)
- 339
- 340 Laboratory session

medRxiv preprint doi: https://doi.org/10.1101/2024.05.24.24307863; this version posted May 25, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Short title – Investigating datases and alternational for the problem of the problem of the preprint of th

- Participants are next invited to attend a laboratory session, consisting of two parts separated by
- a break of approximately 30-60 minutes.
- 343
- 344 Part 1: Standardised neurocognitive testing
- 1. Wechsler Abbreviated Scale of Intelligence (second edition, WASI-II, Wechsler, 2011)
- 346 assesses general cognitive abilities.
- 347 2. A CANTAB Connect cognitive test battery
- 348 (https://www.cambridgecognition.com/products/cognitive-research/) measures
- executive functions, attention, psychomotor response speed, and social cognition.
- 350 3. A performance validity test assesses engagement and motivation (Green et al., 2003).
- 4. Performance evaluations: Participants rate their performance on each test using a 7-
- 352 point Likert-scale.
- 353 Part 2: Experimental cognitive tasks and psychophysiology

After the break, participants complete brief computerised tasks and psychophysiological 354 testing administered with E-Prime experimental software (https://pstnet.com/products/e-355 prime/) and Powerlab psychophysiological 356 а data acquisition system (https://www.adinstruments.com/products/powerlab-daq-hardware). The measures are as 357 358 follows:

- Psychophysiology: Electrodermal activity (skin conductance) and heartrate
 (elctrocardiography) monitor autonomic activation.
- 361 2. Heartbeat tracking and time estimation tasks measure cardiac interoception and362 time perception respectively.
- 363
 363 3. Computerised subjective probes assess momentary psychological and physical
 364 states (Table S1).

medRxiv preprint doi: https://doi.org/10.1101/2024.05.24.24307863; this version posted May 25, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Short title – Investigating datases and alastes are alasted and alastes are alasted and alastes and alastes are alasted and alastes are alasted and alastes and alastes are alasted and alastes areal are alasted and alastes are alasted and alastes

4. Grip contraction task: Participants repeatedly grip a dynamometer device with their 365 dominant hand at maximum effort for short periods, separated by rests. 366 Participants are compensated with a £50 shopping voucher on completion of the 367 laboratory session. 368 Neuroimaging 369 Participants eligible for MRI scanning return to complete the session on a separate day. The 370 session lasts a maximum of 90-minutes, including the following components: 371 1. Structural scans (~10 mins). 372 2. Resting-state functional scan (~10 mins). 373 3. Interoceptive attention task: Participants direct their attention to their heartbeat 374 sensations or an exteroceptive stimulus (~10 mins). 375 4. Affective images task: Participants view blocks of positive, negative and neutral 376 images (International Affective Picture System; Lang et al., 2008). After each 377 block, participants report on momentary physical and psychological states (Table 378 S2). Heartrate and electrodermal activity are monitored throughout (~25-30 mins). 379 5. Interoceptive attention task repeated. 380 Participants are compensated with a £50 shopping voucher on completion of the 381 382 session. 383 *Remote monitoring phase (2-4 weeks duration)* 384 The initial remote monitoring phase includes collection of data on participants' behaviours, 385 experiences and physiological signals for two weeks in their everyday lives. 386

Participants receive support and training from the research team on installation and use
of the smartphone applications (Real Life Exp / Fitbit). The ecological momentary assessment

medRxiv preprint doi: https://doi.org/10.1101/2024.05.24.24307863; this version posted May 25, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Short title – Investigating datases and all the median of the PND: Start by people of the second second

(EMA) protocol involves brief electronic questions daily (6 times per day) on physical and 389 psychological states, and daily events (Table S1). Each data collection point is triggered by a 390 notification from the RealLife Exp application and takes 1-2 minutes to complete. The 391 notifications are sent at pseudorandom intervals during waking hours (9am-9pm). The 392 notifications do not arrive less than one-hour apart. Participants also have the option to enter 393 data on salient daily events as they occur, at any time of the day or night. Two questions on 394 subjective sleep quality (duration, disturbance) are administered each morning. 395 Participants are also asked to wear a FitBit Charge 5 wearable continuously to collect 396 data on potential physiological triggers for FND symptoms, including: 397 Sleep quality and duration – measured daily 398 • Activity – measured continuously 399 • Heartrate – measured continuously 400 401 402 After the initial two-week period, participants with FND and clinical controls are invited to participate in a further two weeks using the RealLife app to log salient daily events, whilst 403 continuing to wear the Fitbit device. 404 All participants are compensated for completion of the remote monitoring phase with a 405 digital £50 shopping voucher and are able to keep the Fitbit device for their personal use if they 406 407 have demonstrated adequate engagement with the study (~80% EMA response rate). 408 Follow-up Procedures 409 Participants with FND and clinical controls are invited to complete 3-, 6- and 12-month follow-410 ups, which involve completing an abbreviated version of the original online questionnaire pack 411 (Figure 1) and a brief call with a member of the research team. They are also invited to provide 412

medRxiv preprint doi: https://doi.org/10.1101/2024.05.24.24307863; this version posted May 25, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Short title – Investigating datases data and the medRxiv a protected set.

their Fitbit data for that follow-up period in pseudonymised format, which can be downloaded

- 414 on request from the Fitbit consumer-facing platform. The research team are available to support
- the participant with all remote activities as needed.
- 416 Participants are compensated for each follow-up with a digital £10 shopping voucher.
- 417 End of Study Procedures

The end of the study is defined as the time at which the last participant completes the final research activity (remote follow-up). Following this, we will inform any regulatory bodies (i.e., the Research Ethics Committee) and the recruitment partners (FND charities and NHS Trusts). After completion of data analysis, the results will be disseminated at academic conferences and in peer-reviewed publications. We will share our findings with the FND-PCAP and other relevant stakeholders via social media, email lists, and/or press releases.

424

425 *Statistical considerations*

426 *Sample size*

The overall target sample size was determined on the basis of a power calculation completed in G*Power (Faul et al., 2007). We estimated that for a mixed model ANOVA/ANCOVA, which will be used to test within- and between-groups variation on the primary endpoint of autonomic arousal, a total sample of 180 (n=45 in each 4 groups) would have 80% power to detect a small effect (f=0.1) with an alpha of 0.05. Therefore, a total sample of 200 participants entering the study will allow for up to five non-completing participants or missing data in each group.

On the basis of our pilot study data, we anticipate that approximately 90% of FND
patients screened will be eligible and approximately 70% will proceed to complete the study;
therefore, we plan to screen ~71 potential participants in each FND group (FS, FMS), to

medRxiv preprint doi: https://doi.org/10.1101/2024.05.24.24307863; this version posted May 25, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Short title – Investigating datases and all the median of the PND: Store in the preprint of the preprint in perpetuity.

437	achieve the target sample size (FS n=50; FMS n=50). We predict that approximately 15
438	participants in each group will be ineligible, unsuitable, or unwilling to participate in the
439	neuroimaging session; therefore, the anticipated sample size for this element of the project is
440	n=35 in each of the four study groups (total $n=140$). For the remote monitoring data analysis,
441	it is estimated that 45 participants per group will allow sufficient statistical power with four
442	variables (affect, dissociation, HR, SCL) entered into a predictive model with momentary
443	FND symptom ratings as the primary outcome variable (Peduzzi et al., 1996).
444	

445 Data processing and statistical analyses

Detailed statistical analysis plans are under development for all elements of the project and
these will be finalised and pre-registered before data analysis commences. The nature of all
data types are outlined in Table S2.

449 The data will be checked for relevant assumptions (normality of distribution, sphericity, homogeneity of variances) prior to analysis. Non-normally distributed data will be 450 transformed, or non-parametric or robust tests used. The amount and nature of missing data 451 and outliers will be examined for all outcome variables. The approach taken with missing 452 data will depend upon the number of missing values and whether the data is judged to be 453 454 missing at random or missing not at random. The options for addressing missing data will include variable or participant exclusion, pairwise deletion, single or multiple imputation. 455 Imputation methods will be used where missing data on a given measure does not exceed 456 457 20%. Outlying data points will be scrutinised and, where appropriate, the values will be Winsorized (replaced with less extreme values). The analyses will be repeated with the 458 original and Winsorized values. Rates of missing data and outliers will be recorded and 459 460 reported, along with any sensitivity analyses conducted.

medRxiv preprint doi: https://doi.org/10.1101/2024.05.24.24307863; this version posted May 25, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Short title – Investigating datases and alastes and al

Recruitment and retention rates will be assessed with descriptive statistics.
Demographics and background variables will be analysed with appropriate between-group
tests including t-tests, Mann-Whitney tests, and/or Analysis of Variance (ANOVA).
Cognitive and experimental task data and autonomic measures will be analysed with
between- or mixed between- and within-group tests, such as ANOVA/ANCOVA with
covariates added where relevant, and/or multivariate regression analyses. Chi-squared tests
will be used for categorical data.

Standardised data pre-processing and analysis methods will be adopted for analysis of 468 neuroimaging data. Pre-processing will include reorientation, motion correction, spatial 469 470 smoothing and normalisation. The neuroimaging data will be analysed with region-of-interest and network connectivity analyses. The primary regions of interest (ROIs) will be: amygdala, 471 periaqueductal grey, and insula. Connectivity analyses will examine functional connectivity 472 patterns between hubs in neural networks involved in affective activation and awareness 473 (amygdala, periaqueductal grey, insula, anterior cingulate cortex) and those involved in motor 474 and cognitive control (motor/premotor areas, dorsolateral prefrontal cortex). 475

The remote monitoring data will be analysed with multilevel modelling, to identify 476 variables (e.g., dissociation, affect, autonomic arousal, life events) that are predictive of FND 477 478 symptom occurrence/worsening in participants' daily lives. Multilevel models are extensions of the traditional regression model, which account for the nested, hierarchical nature of 479 intensive longitudinal data, by including random effects into model coefficients to account 480 for within-participant variation over time. Furthermore, these techniques are suitable for use 481 when there are missing data and unbalanced numbers of observations, as is often the case in 482 remote measurement studies. 483

medRxiv preprint doi: https://doi.org/10.1101/2024.05.24.24307863; this version posted May 25, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Short title – Investigating datases data and the medical protected and the second s

The alpha value to be adopted for most statistical tests will be p≤0.05; however, if
multiple tests are conducted with related data (e.g., sub-scales of a questionnaire, post-hoc
tests following ANOVA, exploratory tests of multiple neural regions [excluding ROIs]), we
will use methods for controlling inflation of familywise error or false discovery rate, such as
Bonferroni or Benjamini-Hochberg corrections respectively.

489

490 Ethical considerations & regulatory approvals

The study is sponsored by King's College London and approved by the North West – Greater 491 Manchester South Research Ethics Committee (ref NW/23/0217). The research will be 492 493 conducted in compliance with the principles of the Declaration of Helsinki (1996), and in accordance with all applicable regulatory requirements including but not limited to the UK 494 policy framework for health and social care research, Trust and Research Office policies and 495 496 procedures and any subsequent amendments. All participants will provide written informed consent prior to participation in the study, as described above (Methods section). 497 This protocol has been developed in consultation with the FND-PCAP and a team of 498

academic and clinical collaborators with expertise in FND research and treatment, or relevant
methodologies. The conduct, progress and results of the study will be reported to these
groups, as well to relevant stakeholders (FND Hope UK, FND Action) and to the approving

502Research Ethics Committee and institutional research governance office (KCL).

503

504 Risk management, adverse events & withdrawal

505 Risk management & safeguarding

506 Some of the research activities could potentially be sensitive or challenging for some

507 participants, such as answering questions regarding physical and mental health, difficult

medRxiv preprint doi: https://doi.org/10.1101/2024.05.24.24307863; this version posted May 25, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Short title – Investigating datases and alternational for the problem of the problem of the preprint in perpetuity.

cognitive tests, exposure to emotionally significant stimuli, discomfort during the
neuroimaging session, and multiple daily prompts during the initial remote monitoring phase.
Our pilot study showed that most participants found these elements of the study
acceptable/tolerable, although we have incorporated feedback to improve participants'
experiences.

The research team will ensure that participants are informed clearly about the nature 513 of all tasks, before each activity commences. All participants will be warned that some of the 514 activities might be challenging and that they may experience some degree of discomfort or 515 stress during specific elements of the research. Participants will be reminded that they are 516 517 free to decline to complete any aspect of the study, or that they may choose to decline specific measures or items, or withdraw from the study at any time, without explanation. The 518 research team will be vigilant for signs of distress throughout the procedures and will pause 519 520 or end procedures if deemed necessary to ensure the participant's well-being. During remote monitoring, the research team will be available by telephone and email to answer questions, 521 trouble-shoot and provide any reassurance that participants may require. The Chief 522 Investigator (SP) will arrange to speak to a participant to discuss any distress experienced 523 during the study, on request. A list of support organisations is included in the Participant 524 525 Information Sheet as standard. Protocols are in place for safeguarding actions to be taken if a participant were to disclose a risk of harm to themselves or another, or if a severe and urgent 526 mental health risk or existing harm became apparent during the course of the study. Adverse 527 528 events occurring during the study will be monitored and recorded by members of the research team, followed-up by SP, and reported to the KCL Research Governance team and the 529 Research Ethics Committee following established procedures. 530

medRxiv preprint doi: https://doi.org/10.1101/2024.05.24.24307863; this version posted May 25, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Short title – Investigating datases data to the median of the PND: IStandy protocole

531

532 Withdrawal/ drop out

- 533 Premature withdrawal of participants may occur for the following reasons:
- participant no longer wishes / is able to take part;
- change in eligibility status is identified;
- a protocol violation.

If a participant withdraws, or is withdrawn from the study, the data collected from them up to that point will be retained in an anonymised format, and the reason for withdrawal will be recorded if voluntarily provided by the participant. No further data would be collected from participants who withdraw or who are withdrawn.

541 Data management

542 All data are stored electronically in secure encrypted databases (e.g., MS Excel), on KCL SharePoint and OneDrive servers. Only immediate members of the research team have access 543 to the databases, as needed. All research data are marked only with a Participant 544 Identification Number (PIN), not with any identifiable data. The linkage data, in which the 545 PIN and identifiable information are associated, is held on a password-protected database, 546 547 securely on KCL servers. Participant identifiable data will not be shared with any third parties, nor will it be shared outside of European Union countries. Participants have the right 548 to withdraw their identifiable data from the study. 549

550 The data that participants share with the research team via the GDPR-compliant 551 Qualtrics, LifeData and Fitbit platforms does not contain any identifiable data and is 552 extracted from the platforms by the research team as soon as possible and stored on secure 553 KCL servers. Participants' data will be deleted from the third-party platforms as soon as 554 possible following data extraction. The data are anonymous to the third parties, who have no medRxiv preprint doi: https://doi.org/10.1101/2024.05.24.24307863; this version posted May 25, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Short title – Investigating datases data and the medRxiv a protected set.

access to any linkage data, although the data are pseudonymous to the research team who will
have access to linkage data.

In publications and other reports of the study findings, only aggregated group level data will be presented, in which no single individual would be identifiable. When the study is complete, the data will be held securely for ten years, as specified by the King's College London data retention policy.

561

562 Financing and Insurance

563 This study is funded by a Medical Research Council Career Development Award to SP

564 [2022-2026, ref MR/V032771/1] and is part-funded by the National Institute for Health and

565 Care Research (NIHR) Maudsley Biomedical Research Centre. The sponsor (KCL) will, at

all times, maintain adequate insurance in relation to the study through its professional

567 indemnity (Clinical Trials) & no-fault compensation in respect of any claims arising as a

result of negligence by its employees, brought by or on behalf of a study participant.

569

570 **Publication and Dissemination**

The anonymised, raw data set will be made available on reasonable request and with
consultation with the KCL Data Management team. The research findings will be presented
at academic conferences and published in peer-reviewed journal articles, as well as being
disseminated to a wider audience through social media channels and/or other public relations
and media outlets.

Participants will be informed that the results will be published and will be offered the
opportunity to receive a summary of the publications and electronic links to the outputs on
request.

medRxiv preprint doi: https://doi.org/10.1101/2024.05.24.24307863; this version posted May 25, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Short title – Investigating datases and alastes and al

579

580 Discussion

Evidence for several hypothesised pathophysiological mechanisms in FND is limited at present 581 582 due to methodological constraints in previous studies (Drane et al., 2020; Pick et a., 2019). This project employs a novel combination of multimodal research methods to rigorously 583 examine several putative mechanisms in FND, at multiple levels of explanation, using 584 585 subjective/experiential, behavioural, and physiological measures. The study is testing causal hypotheses about the role of altered emotional processing, autonomic arousal, dissociation and 586 interoception in the initiation or exacerbation of FND symptoms, directly comparing these 587 588 processes in FS and FMS. We aim to control, or account for, a range of common confounding factors, including comorbid psychiatric symptoms, medication use, and general cognitive 589 functioning. 590

This is the first study to directly compare FND subgroups using such diverse and 591 comprehensive methods in a relatively large sample, including both clinical and healthy 592 593 comparison groups. By examining these mechanistic processes in both laboratory and naturalistic contexts, we will ascertain the consistent influences and underlying processes that 594 might explain the occurrence of FND symptoms across settings. The combination of 595 596 neuroimaging, psychophysiology, and momentary subjective probes will allow us to examine the simultaneous neural, autonomic, and psychological processes that precede subtle variations 597 in subjective FND symptoms from moment-to-moment. The use of remote monitoring 598 technologies will highlight the physiological, psychological and environmental factors 599 influencing FND symptoms in real-time and real-world settings. Moreover, the inclusion of 600 601 longitudinal follow-ups will establish whether specific aetiological factors and mechanistic features are predictive of longer-term clinical outcomes in FS and FMS. 602

medRxiv preprint doi: https://doi.org/10.1101/2024.05.24.24307863; this version posted May 25, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Short title – Investigating datases and an environmentation of PND: Structure of the copyright holder for the preprint in perpetuity.

The results of this study have the potential to lead to significant progression in aetiological and mechanistic models of FND, and will likely uncover meaningful, evidencebased targets for prevention and intervention of FND in future.

606

607

medRxiv preprint doi: https://doi.org/10.1101/2024.05.24.24307863; this version posted May 25, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Short title – Investigating datases and alternational for the problem of the second second

Funding: The study is funded by a Medical Research Council Career Development Award to SP
[MR/V032771/1]. This project also represents independent research part-funded by the National
Institute for Health and Care Research (NIHR) Biomedical Research Centre at South London and
Maudsley NHS Foundation Trust and King's College London. The views expressed are those of
the authors and not necessarily those of the NHS, the NIHR or the Department of Health and
Social Care.

615 **Conflicts of interest:** None.

616

617 Author contributions: Funding acquisition: SP (lead), MH, TC, MAM (supporting).

618 Conceptualisation: SP. Design/methodology: SP (lead), MH, TC, MAM, ASD, LSMM, AATSR,

MJE, LHG, TRN, JSW (supporting). Project administration: SP. Resources: SP (lead), MH, TC

620 (supporting). Writing: SP (original draft/review and editing), MAM, TC, MH, LSMM, LHG, MJE,

TRN, JSW, ASD, BS (review and editing). All authors reviewed and approved the final version ofthe manuscript.

623

medRxiv preprint doi: https://doi.org/10.1101/2024.05.24.24307863; this version posted May 25, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Short title – Investigating datases are all all the median of the median of

624 **References**

625

American Psychiatric Association. (2013). Diagnostic and statistical manual of mentaldisorders (5th ed.).

628

Aybek, S., Nicholson, T. R., O'Daly, O., Zelaya, F., Kanaan, R. A., & David, A. S. (2015).

- Emotion-motion interactions in conversion disorder: an FMRI study. PloS one, 10(4),e0123273.
- 632

Bagby, R. M., Parker, J. A. D, Taylor, G. J. (1994). The twenty-item Toronto Alexithymia
scale—I. Item selection and cross-validation of the factor structure. Journal of Psychosomatic
Research, 38(1), 23-32, https://doi.org/10.1016/0022-3999(94)90005-1.

636

640

Baron-Cohen, S. Wheelwright, R. Skinner, J. Martin and E. Clubley, (2001). The Autism

Spectrum Quotient (AQ) : Evidence from Asperger Syndrome/High Functioning Autism,
 Males and Females, Scientists and Mathematicians. Journal of Autism and Developmental

644 Disorders, 31:5-17.

Briere, J., Weathers, F. W., Runtz, M. (2005). Is dissociation a multidimensional construct?
Data from the Multiscale Dissociation Inventory. J Trauma Stress, 18(3):221-31. doi:
10.1002/jts.20024.

- Broadbent, D.E., Cooper, P.F., FitzGerald, P. and Parkes, K.R. (1982), The Cognitive
 Failures Questionnaire (CFQ) and its correlates. British Journal of Clinical Psychology, 21:
- 652 1-16. https://doi.org/10.1111/j.2044-8260.1982.tb01421.x
- 653

Broadbent, E., Petrie, K. J., Main, J., Weinman, J. (2006). The Brief Illness Perception
 Questionnaire. Journal of Psychosomatic Research, 60(6):631-637,

- Questionnaire. Journal of Psychosomatic Research,
 https://doi.org/10.1016/j.jpsychores.2005.10.020.
- 657 658 Brown, R. J., & Reuber, M. (2016). Psychological and psychi
- Brown, R. J., & Reuber, M. (2016). Psychological and psychiatric aspects of psychogenic
 non-epileptic seizures (PNES): a systematic review. Clinical Psychology Review, 45, 157182.
- Campbell, M., Smakowski, A., Rojas-Aguiluz, M., Goldstein, L., Cardeña, E., Nicholson, T.,
 ... Pick, S. (2023). Dissociation and its biological and clinical associations in functional
 neurological disorder: Systematic review and meta-analysis. BJPsych Open, 9(1), E2.
 doi:10.1192/bjo.2022.597
- 666
- 667 Carson, A., & Lehn, A. (2016). Epidemiology. Handbook of Clinical Neurology, 139, 47-60.668
- Drane, D., Fani, N., Hallett, M., Khalsa, S., Perez, D., & Roberts, N. (2021). A framework for
- 670 understanding the pathophysiology of functional neurological disorder. CNS Spectrums,
- 671 26(6), 555-561. doi:10.1017/S1092852920001789

<sup>Bakvis, P., Roelofs, K., Kuyk, J., Edelbroek, P. M., Swinkels, W. A., & Spinhoven, P.
(2009). Trauma, stress, and preconscious threat processing in patients with psychogenic
nonepileptic seizures. Epilepsia, 50(5), 1001-1011.</sup>

medRxiv preprint doi: https://doi.org/10.1101/2024.05.24.24307863; this version posted May 25, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Short title – Investigating datases and alternational for the problem of the second second

672

Espay, A. J., Maloney, T., Vannest, J., Norris, M. M., Eliassen, J. C., Neefus, E., ... & 673 Szaflarski, J. P. (2018). Impaired emotion processing in functional (psychogenic) tremor: a 674 functional magnetic resonance imaging study. NeuroImage: Clinical, 17, 179-187. 675 676 677 Faul, F., Erdfelder, E., Lang, A.-G., & Buchner, A. (2007). G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behavior 678 Research Methods, 39(2), 175–191. https://doi.org/10.3758/BF03193146 679 680 First, M.B. & Williams, J.B.W. (2021). Quick Structured Clinical Interview for DSM-5® 681 Disorders (QuickSCID-5). American Psychiatric Association Publishing. 682 683 Gabriele, E., Spooner, R., Brewer, R., & Murphy, J. (2022). Dissociations between self-684 reported interoceptive accuracy and attention: Evidence from the Interoceptive Attention 685 Scale. Biological Psychology, 168, 108243. 686 687 Guy, W. B. R. R. (1976). CGI. Clinical global impressions. ECDEU assessment manual for 688 psychopharmacology. 689 690 Hays, R. D., Sherbourne, C. D., Mazel, R. M. (1993). The RAND 36-Item Health Survey 1.0. 691 Health Econ, 2(3):217-27. doi: 10.1002/hec.4730020305. PMID: 8275167. 692 693 Koreki, A., Garfkinel, S. N., Mula, M., Agrawal, N., Cope, S., Eilon, T., ... & Yogarajah, M. 694 (2020). Trait and state interoceptive abnormalities are associated with dissociation and 695 696 seizure frequency in patients with functional seizures. Epilepsia, 61(6), 1156-1165. 697 Kroenke, K., Spitzer, R. L., Williams, J. B. (2001). The PHQ-9: validity of a brief depression 698 699 severity measure. J Gen Intern Med, 16(9):606-13. doi: 10.1046/j.1525-1497.2001.016009606.x. 700 701 Kroenke, K., Spitzer, R. L., Williams, J. B. (2002). The PHQ-15: validity of a new measure 702 703 for evaluating the severity of somatic symptoms. Psychosom Med, 64(2):258-66. doi: 10.1097/00006842-200203000-00008. 704 705 706 Mehling, W. E., Acree, M., Stewart, A., Silas, J., Jones, A. (2018). The Multidimensional Assessment of Interoceptive Awareness, Version 2 (MAIA-2). PLoS One, 13(12). doi: 707 708 10.1371/journal.pone.0208034. 709 Morsy, S. K., Aybek, S., Carson, A., Nicholson, T. R., Stone, J., Kamal, A. M., ... & Kanaan, 710 R. A. (2021). The relationship between types of life events and the onset of functional 711 712 neurological (conversion) disorder in adults: a systematic review and meta-analysis. Psychological Medicine, 1-18. 713 714 715 Mundt, J. C., Marks, I.M., Shear, M.K., Greist, J.H. (2002). The Work and Social Adjustment Scale: a simple measure of impairment in functioning. Br J Psychiatry, 180:461-4. doi: 716 10.1192/bjp.180.5.461. 717 718

medRxiv preprint doi: https://doi.org/10.1101/2024.05.24.24307863; this version posted May 25, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Short title – Investigating datased and alternational for the problem of the problem of the preprint in perpetuity.

719 Nijenhuis, E. R., Spinhoven, P., Van Dyck, R., Van der Hart, O., Vanderlinden, J. (1996).

- 720 The development and psychometric characteristics of the Somatoform Dissociation
- 721 Questionnaire (SDQ-20). J Nerv Ment Dis, 184(11):688-94. doi: 10.1097/00005053-
- 722 199611000-00006.723
- Nijenhuis, E.R.S., Van der Hart, O. and Kruger, K. (2002), The psychometric characteristics
 of the traumatic experiences checklist (TEC): first findings among psychiatric outpatients.
- 726 Clin. Psychol. Psychother, 9: 200-210. https://doi.org/10.1002/cpp.332
- 727
- Peduzzi, P., Concato, J., Kemper, E., Holford, T. R., & Feinstein, A. R. (1996). A simulation
 study of the number of events per variable in logistic regression analysis. Journal of clinical
 epidemiology, 49(12), 1373–1379. https://doi.org/10.1016/s0895-4356(96)00236-3
- 731
- Pick, S., Anderson, D. G., Asadi-Pooya, A. A., Aybek, S., Baslet, G., Bloem, B. R., ... &
- 733 Nicholson, T. R. (2020). Outcome measurement in functional neurological disorder: a
- systematic review and recommendations. Journal of Neurology, Neurosurgery & Psychiatry,
 91(6), 638-649.
- 736
- Pick, S., Goldstein, L. H., Perez, D. L., & Nicholson, T. R. (2019). Emotional processing in
 functional neurological disorder: a review, biopsychosocial model and research agenda.
 Journal of Neurology, Neurosurgery & Psychiatry, 90(6), 704-711.
- 740
- Pick, S., Mellers, J. D., & Goldstein, L. H. (2016). Explicit facial emotion processing in
 patients with dissociative seizures. Psychosomatic medicine, 78(7), 874-885.
- Pick, S., Mellers, J. D., & Goldstein, L. H. (2018a). Autonomic and subjective responsivity to
 emotional images in people with dissociative seizures. Journal of neuropsychology, 12(2),
 341-355.
- 747
- Pick, S., Mellers, J. D., & Goldstein, L. H. (2018b). Implicit attentional bias for facial
 emotion in dissociative seizures: additional evidence. Epilepsy & Behavior, 80, 296-302.
- Pick, S., Rojas-Aguiluz, M., Butler, M., Mulrenan, H., Nicholson, T. R., & Goldstein, L. H.
 (2020). Dissociation and interoception in functional neurological disorder. Cognitive
 Neuropsychiatry, 25(4), 294-311.
- 753 Neuro 754
- Plans, D., Ponzo, S., Morelli, D., Cairo, M., Ring, C., Keating, C. T., ... & Bird, G. (2021).
 Measuring interoception: The phase adjustment task. Biological psychology, 165, 108171.
- 757
 758 Reuber, M. (2009). The etiology of psychogenic non-epileptic seizures: toward a
 759 biopsychosocial model. Neurologic Clinics, 27(4), 909-924.
- 760
- Roberts, N. A., Burleson, M. H., Weber, D. J., Larson, A., Sergeant, K., Devine, M. J., ... &
- Wang, N. C. (2012). Emotion in psychogenic nonepileptic seizures: responses to affective
 pictures. Epilepsy & Behavior, 24(1), 107-115.
- 764
- Ryan, E. G., Vitoratou, S., Goldsmith, K. A., & Chalder, T. (2018). Psychometric Properties
 and Factor Structure of a Long and Shortened Version of the Cognitive and Behavioural

medRxiv preprint doi: https://doi.org/10.1101/2024.05.24.24307863; this version posted May 25, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Short title – Investigating datases are aligned to the problem of the problem of the problem of the preprint of the prepri

- 767 Responses Questionnaire. Psychosomatic medicine, 80(2), 230–237.
- 768 https://doi.org/10.1097/PSY.000000000000536
- 769
- 770 Spitzer, R. L., Kroenke, K., Williams, J. B., Löwe, B. (2006). A brief measure for assessing
- generalized anxiety disorder: the GAD-7. Arch Intern Med,166(10):1092-7. doi:
- 772 10.1001/archinte.166.10.1092.
- 773
- 574 Stone, J., Carson, A., Duncan, R., Roberts, R., Warlow, C., Hibberd, C., ... & Sharpe, M.
- (2010). Who is referred to neurology clinics? The diagnoses made in 3781 new patients.
- Clinical Neurology and Neurosurgery, 112(9), 747-751.

777

- 778 World Health Organization. (2019). International statistical classification of diseases and
- related health problems (11th ed.).

		Screening interview (remote)	Questionnaire pack (online)	Laboratory visit (KCL)	Neuroimaging visit (KCL)	Initial remote monitoring (2-4 weeks)	FU-1 (3m)	FU-2 (6m)	FU-3 (12m)
	Informed consent	x			х	x			
	Demographics	x							
	Medical history	x							
	FNS Questionnaire		х				x	X	X
	CGI-Severity	x							
	CGI-Improvement		х			х	X	X	X
	Quick SCID	x							
	MAIA-2		х				х	X	X
	IAccS		х				x	X	X
	IAttS		х				X	X	X
	TAS-20		х				x	X	X
medDviv	MDI		х				X	X	X
(which	preprint doi, intos://doi.org/10.110 was not ca ddlea-bi/ peer reviev It is) is the author/fund	er, who has granted med	Rxiv a license to disp	ay the preprint in perpetu	ity.	x	X	X
	PHQ-9	made available und	er a CC-BY 4.0 Internatio	nariicense.			X	X	X
	PHQ-15		х				x	X	X
	PDS-5		х				X	X	X
	TEC		х						
	GAD-7		х				х	X	X
	SF-36		х				x	X	X
	WSAS		х				х	X	X
	BIPQ		х				x	X	X
	CBRQ		х				X	X	X
	CFQ		х				x	X	X
	AQ		х						
	WASI-II			x					
	CANTAB battery			x					
	Performance validity test			x					
	Hand grip task			x			<u> </u>	<u> </u>	<u> </u>
	Heartbeat monitoring task(s)			x	x				
	Psychophysiology (ECG, EDA)			x					
	Mock MRI scan			x					
	MRI task training			x	x				
	Structural MRI scans				x				
	Resting state MRI scan				x				
	Task-based MRI scans				x				
	EMA					X			

Figure 1. Flowchart of study procedures

EMA			X			
Fitbit monitoring			x	X	X	x

Key: AQ=Autism Spectrum Quotient; BIPQ=Brief Illness Perceptions Questionnaire; CANTAB=Cambridge Neuropsychological Test Automated Battery; CBRQ=Cognitive Behavioural Responses to Symptoms Questionnaire; CFQ=Cognitive Failures Questionnaire; CGI=Clinical Global Impression; ECG=electrocardiography; EMA= ecological momentary assessment; EDA=electrodermal activity; EEG=electroencephalography; FNS=Functional Neurological Symptoms; GAD-7=Generalized Anxiety Disorder-7; IAccS; Interoceptive Accuracy Scale; ; IAttS; Interoceptive Attention Scale; KCL=King's College London; MAIA-2=Multidimensional Assessment of Interoceptive Awareness-2nd edition; MDI=Multiscale Dissociation Inventory; MRI=magnetic resonance imaging; PDS=Post-Traumatic Diagnostic Scale; PHQ=Patient Health Questionnaire; SCID=Structured Clinical Interview for DSM-5; SDQ-20=Somatoform Dissociation Questionnaire-20; SF-36=Short Form Health Survey-36; TAS-20=Toronto Alexithymia Scale-20; TEC=Traumatic Experiences Checklist; WASI-II=Wechsler Abbreviated Scale of Intelligence-2nd edition; WSAS=Work and Social Adjustment Scale

Figure 1